Interpace Biosciences (IDXG) Proxy filing summary

Executive summary

• Annual Meeting of Shareholders scheduled for August 20, 2026, at 4:00 PM EDT, to be held virtually.

• Proxy materials, including the Notice, Proxy Statement, and Annual Report, are available online for review and voting.

• Proxies appointed are authorized to vote on behalf of shareholders as directed or, if not specified, in line with Board recommendations.

Voting matters and shareholder proposals

• Election of five director nominees to serve until the 2027 Annual Meeting, or staggered terms if Proposal No. 1 is not approved.

• Proposal to amend and restate the Certificate of Incorporation, increasing authorized shares to 200,000,000, providing for blank check preferred stock, and declassifying the Board for annual elections.

• Proposal to grant authority for a reverse stock split at a ratio between one-for-two and one-for-ten.

• Approval of the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan.

• Advisory vote on executive compensation and ratification of EisnerAmper, LLP as independent auditor for fiscal year ending December 31, 2026.

Board of directors and corporate governance

• Board recommends voting for all director nominees and for all proposals.

• If declassification is not approved, directors will be elected to staggered terms by class.